An evidence-based review of NX1207 and its potential in the treatment of benign prostatic hyperplasia

Overview of attention for article published in Research and Reports in Urology, July 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#32 of 223)
High Attention Score compared to outputs of the same age (83rd percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

So far, Altmetric has seen 5 X posts from 4 X users, with an upper bound of 7,527 followers.

#RECORDATI $NYMX evidence-based review NX-1207 http://t.co/QVY1nElAGf $ACAD $VVUS $OREX $ARIA $MNKD $ACHN $QQQ $CDLX $GILD $SNSS @FiboZero

$NYMX $REC.MI An evidence-based review of NX1207 http://t.co/4JQTytXrJp $ACAD $VVUS $OREX $ARIA $MNKD $ACHN Paracelsus Medical University

Intraprostatic drug injection for BPH treatment. A new pro-apoptopic agent, NX1207 shows promise results. http://t.co/untmBWPiE1 #prostate

Intraprostatic drug injection for BPH treatment. A new pro-apoptopic agent, NX1207 shows promise results. http://t.co/untmBWPiE1 #prostate

AN evidence-based review of NX1207 and its potential in the treatment of benign prostatic hyperplasia. http://t.co/mcAjAIuRh3